<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157335</url>
  </required_header>
  <id_info>
    <org_study_id>D3252C00002</org_study_id>
    <nct_id>NCT04157335</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)</brief_title>
  <acronym>ORCHID</acronym>
  <official_title>A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-group, international,
      multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of
      benralizumab 30 mg administered subcutaneously (SC) versus placebo in patients with severe
      nasal polyposis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 148 patients will be randomized to receive benralizumab 30 mg SC or matching
      placebo. After enrolment, eligible patients will enter a 5-week screening/run in period.
      Patients who meet eligibility criteria will be randomised 1:1 at Week 0 (Day 0) to receive
      either placebo or benralizumab 30 mg SC every 4 weeks for the first 3 doses (Weeks 0, 4 and
      8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48). An end of treatment visit will
      be conducted at Week 56.The first up to 74 patients that complete the 56-week treatment will
      have a 24-week follow-up (FU) period without dosing to assess durability of benefit. These
      patients will have the FU for the final safety assessment at week 80. The remaining patients
      will have a last FU visit 12 weeks after last dose for final safety assessments at week 60.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2019</start_date>
  <completion_date type="Anticipated">July 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endoscopic total nasal polyp score</measure>
    <time_frame>Baseline and Week 56</time_frame>
    <description>Change in endoscopic total nasal polyp score (nasal polyp score range from 0 to 8, higher scores mean a worse outcome)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nasal blockage score</measure>
    <time_frame>Baseline and week 56</time_frame>
    <description>Change in mean nasal blockage score (The severity of nasal blockage can be rated as 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lund Mackay Score</measure>
    <time_frame>Baseline and week 56</time_frame>
    <description>Change in Lund Mackay Score (Lund Mackay Score range from 0 to 24, higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal polyp surgery</measure>
    <time_frame>By week 56</time_frame>
    <description>Time to first nasal polyp surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with surgery for nasal polyp</measure>
    <time_frame>By week 56</time_frame>
    <description>Proportion of patients with surgery for nasal polyp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SinoNasal Outcome Test (SNOT-22) score</measure>
    <time_frame>Baseline and week 56</time_frame>
    <description>Change in SinoNasal Outcome Test (SNOT-22) score (SNOT-22 can be rated via a 6-point scale (0- No Problem to 5- Problem as bad as it can be)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with systemic corticosteroids use for nasal polyp</measure>
    <time_frame>By week 56</time_frame>
    <description>Proportion of patients with systemic corticosteroids use for nasal polyp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First systemic corticosteroids course for nasal polyp</measure>
    <time_frame>By week 56</time_frame>
    <description>Time to first systemic corticosteroids course for nasal polyp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Courses of systemic corticosteroids for nasal polyp</measure>
    <time_frame>By week 56</time_frame>
    <description>Number of courses of systemic corticosteroids for nasal polyp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total systemic corticosteroids dose used</measure>
    <time_frame>By Week 56</time_frame>
    <description>Systemic corticosteroids use for relief of nasal symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of systemic corticosteroids use for nasal polyp</measure>
    <time_frame>By Week 56</time_frame>
    <description>Systemic corticosteroids use for relief of nasal symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal symptom score(s) as captured in the daily diary</measure>
    <time_frame>Baseline and week 56</time_frame>
    <description>Change in nasal symptom score(s) as captured in the daily diary (severity of each symptom at its worst can be rated using a 4-point verbal rating scale (0‒none to 3‒severe) )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>University of Pennsylvania Smell Identification Test (UPSIT) score</measure>
    <time_frame>Baseline and week 56</time_frame>
    <description>Change in University of Pennsylvania Smell Identification Test score (UPSIT scores are based on number of correctly identified odors (score range 0 to 40), higher scores mean a better outcome.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sinus severity score by quantitative CT analysis</measure>
    <time_frame>Baseline and week 56</time_frame>
    <description>Change in sinus severity score by Quantitative CT analysis (sinus severity score range from 0 to 100%, higher scores mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zinreich score (modified LMS)</measure>
    <time_frame>Baseline and week 56</time_frame>
    <description>Change in Zinreich score (modified LMS) (Zinreich score range from 0-54, higher scores mean a worse outcome.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 36-item Health survey, Version 2 (SF-36v2)</measure>
    <time_frame>Baseline and week 56</time_frame>
    <description>Change in Short Form 36-item Health survey, Version 2 (SF-36v2), Physical Component Score and Mental Component Score and domains (each item is scored 0-100, with higher scores meaning better outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum trough concentrations</measure>
    <time_frame>Week 0, 16, 24, 40, 56, 60, 68, 80.</time_frame>
    <description>Summary of serum concentration of benralizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies</measure>
    <time_frame>Week 0, 16, 24, 40, 56, 60, 68, 80.</time_frame>
    <description>Incidence of anti-drug antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Nasal Polyposis</condition>
  <arm_group>
    <arm_group_label>Benralizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benralizumab administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Benralizumab 30 mg</intervention_name>
    <description>Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.
Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).</description>
    <arm_group_label>Benralizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matched placebo</intervention_name>
    <description>Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.
Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the informed consent form and in this
             protocol.

          2. Subject must be 18 to 75 years of age inclusive, at the time of signing the informed
             consent form.

          3. Patients with bilateral sinonasal polyps that, despite treatment with standard of care
             including a history of treatment with Systemic corticosteroids (oral, parenteral) or
             prior surgery for Nasal polyps have severity consistent with a need for surgery as
             described by:

               -  A minimum total Nasal polyp score of 5 out of a maximum score of 8 (with a
                  unilateral score of at least 2 for each nostril) at Visit 1 and continuously
                  maintained at Visit 2 to meet the randomisation criterion as determined by the
                  study Imaging Core Lab

               -  Ongoing symptoms for at least 12 weeks prior to Visit 1

               -  Patient-reported moderate to severe nasal blockage (score 2 or 3) over the
                  2-weeks prior to Visit 1 (2-week recall assessment of symptoms, scores 0-none to
                  3-severe).

          4. CT Lund Mackay score for ethmoid ≥ maxillary as determined by the study Imaging Core
             lab.

          5. Patients meet one of the following criteria:

               -  Blood eosinophil count &gt; 5% as determined by central lab

               -  Blood eosinophil count is &gt;2% and ≤ 5% as determined by central lab with a
                  diagnosis of asthma and/or Aspirin exacerbated respiratory disease or NSAID
                  exacerbated respiratory disease

          6. Patients who are on Intranasal corticosteroids or leukotriene receptor antagonists
             (LTRAs), need to be at stable dose for at least 30 days prior to Visit 1.

          7. SNOT-22 total score ≥ 20 at enrolment (Visit 1).

        Exclusion Criteria:

          1. Patients who have undergone any nasal and/or sinus surgery within 3 months prior to
             Visit 1.

          2. Patients with conditions or concomitant disease that makes them non evaluable for the
             co-primary efficacy endpoint such as:

               -  Unilateral antrochoanal polyps;

               -  Nasal septal deviation that occludes at least one nostril;

               -  Acute sinusitis, nasal infection, or upper respiratory infection at screening or
                  in the 2 weeks before screening;

               -  Current rhinitis medicamentosa;

               -  Allergic fungal rhinosinusitis or allergic fungal sinusitis;

               -  Nasal cavity tumours.

          3. Patients experiencing an asthma exacerbation requiring systemic (oral and/or
             parenteral) corticosteroids treatment or hospitalisation (&gt;24hrs) for treatment of
             asthma within 4 weeks prior to Visit 1.

          4. Known history of allergy or reaction to any component of the Investigational product
             formulation.

          5. Prior/concomitant therapy: use of immunosuppressive medication (including but not
             limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, or any
             experimental anti-inflammatory therapy) within 3 months prior to V1 and during the
             study period.

          6. Alanine aminotransferase or aspartate aminotransferase level ≥ 3 times the upper limit
             of normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luo Zhang, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dalian</city>
        <zip>116001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foshan</city>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinan</city>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanning</city>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Qingdao</city>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xian</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yantai</city>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiba-shi</city>
        <zip>262-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ichikawa-shi</city>
        <zip>272-0143</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <zip>211-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kumamoto-shi</city>
        <zip>860-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meguro-ku</city>
        <zip>153-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meguro-ku</city>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minato-ku</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moriguchi-shi</city>
        <zip>570-0074</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <zip>540-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yoshida-gun</city>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh City</city>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>70000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hochiminh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Thailand</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benralizumab</keyword>
  <keyword>Nasal Polyposis</keyword>
  <keyword>Eosinophilic Chronic Rhinosinusitis with Nasal Polyposis</keyword>
  <keyword>Nasal Polyps</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benralizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

